Want to see ABOS full AI Analyst Report?
ABOS Stock Chart & Stats
$2.82
-$0.08(-4.37%)
At close: 4:00 PM EST
$2.82
-$0.08(-4.37%)
Day’s Range― - ―
52-Week Range$1.19 - $3.60
Previous CloseN/A
Volume101.31K
Average Volume (3M)556.33K
Market Cap
$195.01M
Enterprise Value$115.66M
Total Cash (Recent Filing)$128.40M
Total Debt (Recent Filing)$31.16M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Aug 17, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding72,227,580
10 Day Avg. Volume902,974
30 Day Avg. Volume556,328
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.81
Price to Sales (P/S)0.00
P/FCF Ratio-1.11
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.51K
Enterprise Value/Ebitda-1.06
Forecast
1Y Price Target
$8.00Price Target Upside183.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Execution: ALTITUDE-AD On TrackA well-powered, fully enrolled Phase II (≈542 subjects) with enrollment completed in ~10 months and a planned late‑2026 topline reduces execution risk versus earlier-stage programs. Consistent trial conduct and efficient screening materially increase the likelihood of a timely, interpretable readout driving strategic decisions.
EBD Program Advances And DifferentiationProgress nominating and licensing two Enhanced Brain Delivery candidates and strong primate data (14–40x brain exposure) represent structural pipeline diversification. If translated clinically, EBD could widen addressable patients, enable subcutaneous dosing and reduce reliance on a single IV asset, strengthening long-term franchise potential.
Low Leverage With Improving Capital StructureAn improved debt-to-equity ratio (~0.16 TTM) indicates relatively modest leverage for a clinical-stage biotech, reducing bankruptcy and interest-rate sensitivity. Structurally lower debt enhances financial flexibility for fundraising or partnering and preserves strategic optionality during multi-year development cycles.
Bears Say
Sustained Negative Cash GenerationPersistent and growing negative free cash flow shows the company is consuming capital to advance trials rather than generating cash. Over months this requires repeated external financing, dilutes existing shareholders, constrains discretionary R&D, and makes long-term program funding contingent on capital markets or partners rather than internal cash generation.
Limited Cash Runway Into Early 2027A runway through only early 2027 creates a material near-term financing imperative. Fundraising needs can compress timelines, force accelerated partnering or non‑optimal licensing terms, and introduce execution risk if market windows or data timing shift, making multi‑year development plans contingent on near-term capital raises.
Binary Phase II Outcome And Class SkepticismThe company’s clinical trajectory and ability to attract partners hinge on a single Phase II readout. Given ongoing skepticism of the anti‑amyloid class and competitive alternatives, a negative or equivocal result would materially impair strategic options, revenue prospects and future fundraising, creating lasting downside risk.
Acumen Pharmaceuticals News
ABOS FAQ
What was Acumen Pharmaceuticals, Inc.’s price range in the past 12 months?
Acumen Pharmaceuticals, Inc. lowest stock price was $1.19 and its highest was $3.60 in the past 12 months.
What is Acumen Pharmaceuticals, Inc.’s market cap?
Acumen Pharmaceuticals, Inc.’s market cap is $195.01M.
When is Acumen Pharmaceuticals, Inc.’s upcoming earnings report date?
Acumen Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 37 days.
How were Acumen Pharmaceuticals, Inc.’s earnings last quarter?
Acumen Pharmaceuticals, Inc. released its earnings results on May 12, 2026. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.403 by $0.073.
Is Acumen Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Acumen Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Acumen Pharmaceuticals, Inc. pay dividends?
Acumen Pharmaceuticals, Inc. does not currently pay dividends.
What is Acumen Pharmaceuticals, Inc.’s EPS estimate?
Acumen Pharmaceuticals, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Acumen Pharmaceuticals, Inc. have?
Acumen Pharmaceuticals, Inc. has 72,227,580 shares outstanding.
What happened to Acumen Pharmaceuticals, Inc.’s price movement after its last earnings report?
Acumen Pharmaceuticals, Inc. reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.403. Following the earnings report the stock price went down -3.502%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in ABOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acumen Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (183.69% Upside)
$8.00 (183.69% Upside)
Blogger Sentiment
Bullish
ABOS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 6.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $89.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.00%
12-Months-Change
Fundamentals
Return on Equity
-123.07%
Trailing 12-Months
Asset Growth
-34.65%
Trailing 12-Months
Company Description
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
ABOS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive tone driven by on-track clinical execution (ALTITUDE-AD), imminent milestones (ALTITUDE top-line readout late 2026; licensing decision for two EBD candidates in Q2 2026), encouraging preclinical EBD data (≈14–40x brain exposure), and controlled operating expenses. Key risks tempering the outlook include a cash runway only into early 2027 (necessitating future financing if programs extend), pending binary Phase II results that will determine the program's trajectory, competition and skepticism around the amyloid class, and the EBD program still being preclinical with an IND targeted for mid-2027.View all ABOS earnings summariesABOS Stock 12 Month Forecast
Average Price Target
$8.00
▲(183.69% Upside)
Technical Analysis
Ownership Overview
32.76% Insiders
5.71% Mutual Funds
0.02% Other Institutional Investors
56.85% Public Companies and
Individual Investors